Organicell Regenerative Medicine Inc (OTCMKTS:BPSR) stock is moving up sharply as investors reacted positively after the news.
Major Trigger:
Organicell Announces Positive Results of Their Expanded Access Trial for the Treatment of Mild to Moderate COVID-19 Using ZofinTM
Key Highlights:
- BPSR announced the outcome of their expanded access (EA) intermediate size patient population trial (NCT04657406) which:
- Met endpoints for safety and efficacy in patients with mild to moderate COVID-19
- Mitigated mild and moderate symptoms, Improved pulmonary opacities detected in chest X-rays, Improved inflammatory biomarkers
- The trial was conducted at United Memorial Medical Center (UMMC) in Houston, TX. The administration of ZofinTM was well tolerated in all enrolled subjects, with no adverse events. Chest X-ray data demonstrated that 75% of subjects had bilateral opacities caused by COVID-19 infection at day 0 (baseline), prior to ZofinTM treatment. Thirty days after ZofinTM treatment, chest X-ray data showed 83% of treated subjects had normal lung imaging, indicating complete recovery. There was also a significant decrease in biomarker levels like CRP, IL-6, and TNF-α at day 14, 21, and 30 when compared to the respective control with p-values less than p < 0.05, p < 0.01 and p < 0.001, respectively. Organicell intends to submit results for scientific peer review and publication.
Market Reactions
As of 10:52, BPSR stock jumped by 20% at $0.1680. Total volume so far stood at 5.86 million shares, compared to its average volume of 7.49 million shares. The stock moved within a range of $0.1511 – 0.2100 after opening at $0.170.
 Stock Soars){kind=link}